海泰新光(688677) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 reached ¥93,489,632.76, representing a year-on-year increase of 39.21% due to increased sales of medical endoscope instruments[5] - Net profit attributable to shareholders was ¥35,792,018.79, up 36.98% year-on-year, while the net profit after deducting non-recurring gains and losses increased by 34.19%[5] - Total revenue for Q1 2022 reached ¥93,489,632.76, a 39.2% increase from ¥67,158,223.15 in Q1 2021[20] - Net profit attributable to shareholders for Q1 2022 was ¥35,792,018.79, up from ¥26,130,147.11 in Q1 2021, representing a 37.9% growth[21] - Operating profit for Q1 2022 was ¥41,243,659.55, compared to ¥29,498,981.37 in Q1 2021, indicating a 39.9% increase[20] Cash Flow and Assets - The net cash flow from operating activities decreased by 25.21% year-on-year, primarily due to a government subsidy of ¥12.73 million received in Q1 2021; excluding this, the cash flow would have increased by 24.81%[7] - Cash flow from operating activities in Q1 2022 was ¥23,469,085.19, down from ¥31,378,337.96 in Q1 2021[22] - The company's cash and cash equivalents as of March 31, 2022, amount to ¥317,399,284.25, a decrease from ¥723,080,364.17 on December 31, 2021[18] - Cash and cash equivalents at the end of Q1 2022 were ¥317,365,068.90, down from ¥795,720,865.79 at the end of Q1 2021[23] - The company reported a net cash outflow from investing activities of ¥427,691,546.92 in Q1 2022, compared to an outflow of ¥15,256,825.03 in Q1 2021[23] Research and Development - Research and development expenses totaled ¥10,630,408.34, marking a 45.17% increase compared to the same period last year, driven by an increase in R&D personnel and project investments[7] - Research and development expenses for Q1 2022 totaled ¥10,630,408.34, up from ¥7,322,569.49 in Q1 2021, reflecting a 45.5% increase[20] - The proportion of R&D investment to operating revenue increased by 0.47 percentage points to 11.37%[6] - Research and development expenses for Q1 2022 were CNY 4,262,572.05, an increase of 11.5% from CNY 3,824,385.44 in Q1 2021[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 2,859[14] - The largest shareholder, Qingdao Poda Enterprise Management, holds 10,920,000 shares, representing 12.55% of total shares[14] - The second largest shareholder, Zheng Anmin, holds 10,500,000 shares, accounting for 12.07%[14] Financial Position - The total assets at the end of the reporting period were ¥1,209,559,169.78, reflecting a 2.35% increase from the end of the previous year[6] - Total assets as of Q1 2022 amounted to ¥1,209,559,169.78, compared to ¥1,181,785,162.62 at the end of Q1 2021[20] - Total liabilities decreased to ¥79,599,509.84 in Q1 2022 from ¥87,043,804.13 in Q1 2021, a reduction of 8.3%[20] - The total current assets as of March 31, 2022, were CNY 634,640,443.66, a decrease of 4.3% from CNY 661,892,651.67 at the end of 2021[26] - The total liabilities decreased to CNY 78,400,640.36 as of March 31, 2022, down from CNY 118,663,389.52 at the end of 2021, representing a reduction of 33.9%[26] - The company’s total equity increased to CNY 870,997,432.68 as of March 31, 2022, up from CNY 831,443,152.87 at the end of 2021, reflecting a growth of 4.8%[26] Other Information - The company has not reported any significant new strategies or product developments during the quarter[17] - There are no significant changes in the top ten shareholders' participation in margin trading or securities lending[16] - The company has not provided any future performance guidance or outlook in the current report[17] - The financial statements for the quarter are unaudited[17] - The company plans to continue investing in new technologies and market expansion strategies to drive future growth[32]